Meeting
2021 Gastrointestinal Cancers Symposium
Molecular profiling of advanced pancreatic ductal adenocarcinoma (PDAC): Role of ctDNA.
Authors
Angela Lamarca
Department of Medical Oncology, The Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom
Angela Lamarca , Mairead Geraldine McNamara , Richard Hubner , Juan W. Valle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Pancreatic Cancer
Track
Pancreatic Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 425)
DOI
10.1200/JCO.2021.39.3_suppl.425
Abstract #
425
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA.
First Author: Daniel V.T. Catenacci
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The impact of Wnt pathway alterations including RNF43, GNAS, CTNNB1, and APC on prognosis and potential therapeutic vulnerability in pancreatic adenocarcinoma (PDAC).
First Author: Naoko Takebe
Poster
2023 ASCO Annual Meeting
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.
First Author: Amit Mahipal
Poster
2023 ASCO Annual Meeting
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
First Author: Seth Andrew Wander